Apart from its anti-cancer drugs Fusilev and Zevalin, Spectrum has 10 other oncology drug candidates that are now in clinical development, two of them in phase 3 clinical trials and several undergoing phase 1 and 2 clinical studies.
FORBES: Why This Tiny But Profitable Biotech May Be Gobbled Up By Big Pharma